Form 8-K - Current report:
SEC Accession No. 0001193125-25-230348
Filing Date
2025-10-03
Accepted
2025-10-03 16:51:54
Documents
13
Period of Report
2025-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d807496d8k.htm   iXBRL 8-K 36075
2 EX-2.1 d807496dex21.htm EX-2.1 641392
  Complete submission text file 0001193125-25-230348.txt   943358

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA halo-20250930.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE halo-20250930_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE halo-20250930_pre.xml EX-101.PRE 10813
15 EXTRACTED XBRL INSTANCE DOCUMENT d807496d8k_htm.xml XML 3497
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 251374673
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)